| Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health | 09/16 07:00 | globenewswire.com |
| Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies | 08/29 08:15 | globenewswire.com |
| OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV | 08/09 09:00 | accesswire.com |
| Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds | 08/08 19:01 | globenewswire.com |
| Can-Fite Provides Namodenoson Patent Update | 07/29 07:00 | globenewswire.com |
| Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8 | 07/17 07:00 | globenewswire.com |
| Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer | 07/11 07:00 | globenewswire.com |
| Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver | 06/24 07:00 | businesswire.com |
| Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study | 06/10 07:00 | businesswire.com |
| Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study | 06/05 07:00 | businesswire.com |